ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CBAY Cymabay Therapeutics Inc

32.46
0.00 (0.00%)
Pre Market
Last Updated: 06:35:51
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 32.42
Ask Price 32.50
News -
Day High

Low
7.2609

52 Week Range

High
32.48

Day Low
Company Name Stock Ticker Symbol Market Type
Cymabay Therapeutics Inc CBAY NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 32.46 06:35:51
Open Price Low Price High Price Close Price Prev Close
32.46
Trades Volume Avg Volume 52 Week Range
0 0 - 7.2609 - 32.48
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 32.46 USD

Cymabay Therapeutics (CBAY) Options Flow Summary

Overall Flow

Bullish

Net Premium

41k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

Cymabay Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
3.72B 114.72M - 31.07M -105.37M -0.92 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cymabay Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CBAY Message Board. Create One! See More Posts on CBAY Message Board See More Message Board Posts

Historical CBAY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week32.4332.4832.4232.453,358,7180.030.09%
1 Month32.1432.4832.1432.313,220,9980.321.00%
3 Months23.2132.4822.1130.693,939,8699.2539.85%
6 Months16.0432.4812.3225.672,876,14316.42102.37%
1 Year9.6532.487.260919.822,425,43022.81236.37%
3 Years4.8132.481.670114.311,272,05327.65574.84%
5 Years13.3532.481.019.711,473,64619.11143.15%

Cymabay Therapeutics Description

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta.

Your Recent History

Delayed Upgrade Clock